Myriad Genetics (MYGN) Non-Current Debt (2016 - 2026)

Myriad Genetics (MYGN) has reported Non-Current Debt for 10 consecutive years, with $120.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Debt rose 102.87% year-over-year to $120.3 million; the TTM figure through Mar 2026 stood at $120.3 million (up 102.87% YoY), while the FY2025 annual figure was $119.9 million, up 202.78% from the prior year.
• Non-Current Debt steadied at $120.3 million in Q1 2026 per MYGN's latest filing, from $119.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $120.3 million in Q1 2026 and bottomed at $38.4 million in Q2 2023.
• Historically, Non-Current Debt has averaged $62.8 million across 4 years, with a median of $39.0 million in 2024.
• Annual changes were most pronounced in 2024 — Non-Current Debt climbed 1.04% — and 2025, when it jumped 206.41%.
• Myriad Genetics' Non-Current Debt stood at $38.5 million in 2023, then grew by 2.86% to $39.6 million in 2024, then surged by 202.78% to $119.9 million in 2025, then rose by 0.33% to $120.3 million in 2026.
• Business Quant data shows MYGN's Non-Current Debt at $120.3 million in Q1 2026, $119.9 million in Q4 2025, and $119.5 million in Q3 2025.